Thiol-Reactive Bifunctional Chelators for the Creation of Site-Selectively Modified Radioimmunoconjugates with Improved Stability
Authors:
- 6 March 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 29 (4) , 1364-1372
Abstract
Maleimide-bearing bifunctional chelators have been used extensively for the site-selective bioconjugation and radiolabeling of peptides and proteins. However, bioconjugates obtained using these constructs inevitably suffer from limited stability in vivo, a trait that translates into suboptimal activity concentrations in target tissues and higher uptake levels in healthy, nontarget tissues. To circumvent this issue, phenyloxadiazolyl methylsulfones have previously been reported as alternatives to maleimides for thiol-based ligations, but these constructs have scarcely been used in the field of radiochemistry. In this report, we describe the synthesis of two thiol-reactive bifunctional chelators for 89Zr and 177Lu based on a new, easy-to-make phenyloxadiazolyl methylsulfone reagent, PODS. Radioimmunoconjugates created using these novel bifunctional chelators displayed in vitro stability that was higher than that of their maleimide-derived cousins. More importantly, positron emission tomography imaging in murine models of cancer revealed that a 89Zr-labeled radioimmunoconjugate created using a PODS-bearing bifunctional chelator produced a rate of uptake in nontarget tissues that is significantly lower than that of its analogous maleimide-based counterpart.Keywords
Funding Information
- National Cancer Institute (R01CA204167, 4R00CA178205-02)
- National Institute on Minority Health and Health Disparities (G12MD007599)
- TeamConnor Childhood Cancer Foundation
This publication has 33 references indexed in Scilit:
- 89Zr, a Radiometal Nuclide with High Potential for Molecular Imaging with PET: Chemistry, Applications and Remaining ChallengesMolecules, 2013
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesNature Biotechnology, 2012
- Tunable Degradation of Maleimide–Thiol Adducts in Reducing EnvironmentsBioconjugate Chemistry, 2011
- Site-Specific Conjugation of Monodispersed DOTA-PEGn to a Thiolated Diabody Reveals the Effect of Increasing PEG Size on Kidney Clearance and Tumor Uptake with Improved 64-Copper PET ImagingBioconjugate Chemistry, 2011
- ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer ModelJournal of Nuclear Medicine, 2010
- 89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In VivoJournal of Nuclear Medicine, 2010
- Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPETNuclear Medicine and Biology, 2010
- A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinomaCancer Science, 2006
- Site-specific conjugation of bifunctional chelator BAT to mouse IgG1 Fab1 fragmentActa Pharmacologica Sinica, 2006
- Site-specific Conjugation on Serine → Cysteine Variant Monoclonal AntibodiesJournal of Biological Chemistry, 2000